Peer-reviewed veterinary case report
MDR1 gene levels predict chemo tolerance and outcome in dogs
By Gramer, I et al.·Published in Veterinary and comparative oncology·2015·Institute of Pharmacology and Toxicology, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Determination of MDR1 gene expression for prediction of chemotherapy tolerance and treatment outcome in dogs with lymphoma.
- Species:
- dog
Plain-English summary
A group of 27 dogs with lymphoma (a type of cancer) received standard chemotherapy, and researchers looked at a specific gene (MDR1) to see if it could predict how well the dogs would tolerate the treatment. They found that dogs with lower levels of this gene were more likely to have severe side effects from the chemotherapy. Additionally, four dogs that showed a significant increase in the gene's expression during treatment experienced disease progression. This suggests that monitoring the MDR1 gene levels could help veterinarians anticipate treatment reactions and outcomes in dogs undergoing chemotherapy for lymphoma.
People also search for: dog lymphoma treatment side effects · chemotherapy for dogs with cancer · MDR1 gene testing in dogs
Abstract
The multidrug resistance gene 1(MDR1) expression levels were analysed in 27 dogs with different types of malignant lymphomas receiving a standard chemotherapy protocol. Blood samples were used for MDR1 real-time PCR expression analysis. Treatment tolerance and outcome were evaluated on a regular basis by clinical examination and client questioning. Dogs developing severe adverse effects under treatment showed significantly lower basal MDR1 gene expression levels when compared with those who tolerated the drugs well. In the longitudinal MDR1 gene expression analysis during treatment, four dogs showed a greater than two-fold MDR1 up-regulation, compared to baseline expression. All four of these dogs, but none of the others, showed disease progression. In conclusion, basal and follow-up MDR1 gene expression levels could be of predictive value for the occurrence of severe adverse drug reactions and/or the development of MDR during chemotherapy for lymphoma in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23834200/